AVXL Financials 07/15/2014 21:00:25 Anavex Life S

AVXL Financials 07/15/2014 21:00:25
Anavex Life Sciences Corp.
Period Ending Sep 30, 2013 Sep 30, 2012 Sep 30, 2011 Sep 30, 2010
Total Revenue - - - -
Cost of Revenue - - 48 -
Gross Profit - - (48) -
Operating Expenses
Research and Development 264 2,654 2,597 2,729
Sales, General and Admin. 1,697 1,523 3,393 2,745
Non-Recurring Items 176 143 141 173
Other 1 2 2 1
Operating Income (2,137) (4,321) (6,181) (5,648)
Income From Continuing Operations
Add'l Income/Expense Items (1,511) (3,842) (1,036) (2,850)
Earnings Before Interest and Tax (3,153) (4,334) (7,018) (8,498)
Interest Expense 51 138 90 285
Earnings Before Tax (3,205) (4,472) (7,108) (8,783)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (3,700) (8,302) (7,307) (8,783)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (3,700) (8,302) (7,307) (8,783)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (3,700) (8,302) (7,307) (8,783)